Last reviewed: May 1, 2026
Listen now
Episode breakdown
Key takeaways
- Early product decisions in MedTech significantly impact long-term commercial success and can create compounding problems if not carefully considered.
- Understanding regulatory pathways is crucial; for example, 510(k) clearances average four years, while PMA programs typically require seven to nine years.
- Applying an engineering mindset, including hypothesis testing and iterative refinement, can de-risk product development in MedTech.
- Careful selection of regulatory pathways, including considering claims limits and feature alignment, is essential for new medical devices.
- Effective product management involves strategic market segmentation to target the appropriate user base and maximize commercial viability.
- Integrating cybersecurity considerations from the outset aligns with the FDA's emphasis on device security and ensures long-term product integrity and patient safety.
Product decisions made during early development determine commercialization outcomes years later. Wrong choices about regulatory pathways, feature sets, and market segments create compounding problems limiting commercial success.
Christian Espinosa and Trevor Slattery explore product management with Brent Lavin, Chief Product Catalyst of Ironwood MedTech Partners, covering why 510(k) pathways average four years while PMA programs require seven to nine years, and how feature set alignment shapes success.
The engineering mindset applies hypothesis testing to product development through iterative refinement.
Practical for MedTech founders and product teams.
Frequently asked questions
Bring this work to your device
Need help with fda premarket cybersecurity?
Blue Goat Cyber delivers fda premarket cybersecurity services for medical device manufacturers - from threat modeling to FDA-ready reports.
FDA Premarket Cybersecurity ServicesMore on FDA Premarket Cybersecurity
Keep listening
-
Episode 69
Science Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital
With Varun Turlapati
-
Episode 65
Why Clinical Trials Are the Most Expensive Capital Outlay for Startups with Rob Bedford, CEO of Franklyn Health
With Rob Bedford
-
Episode 64
Traceability Requirements and Documentation Audit Trails with Dr. Basant Bajpai, CEO of Compliance MedQRA
With Dr. Basant Bajpai
-
Episode 62
Edge Cases, Alarm Fatigue, and Why AI Cannot Replace Clinical Judgment with Brandon Fertig, Senior Manager at Philips Healthcare
With Brandon Fertig